In contrast with the use of genetically engineered mouse (GEM) models to develop SMO inhibitors for the treatment of BCC and MB, numerous groups employed human tumour cell lines and xenograft models in preclinical studies to extend the potential application of SMO inhibitors to a broad range of human cancers. This evidence concerns the gene SMO and skin basal cell carcinoma.